Attached files

file filename
EX-99.1 - PRESS RELEASE - MEDIFAST INCv301147_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) February 1, 2012

 

MEDIFAST, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-23016   13-3714405
(State or other jurisdiction   (Commission File Number)   (IRS Employer
of incorporation or organization)       Ident. No.)

 

11445 Cronhill Drive, Owing Mills, Maryland   21117
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code (410)-581-8042

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
£ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
£ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
£ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.02(b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On February 1, 2012, the Board of Directors of Medifast, Inc. elected to appoint Executive Chairman Michael C. MacDonald to the additional post of CEO, effective as of February 8, 2012. This appointment coincides with the February 8, 2012 expiration of the employment contract of the Company’s current CEO, Michael S. McDevitt. In addition to departing as CEO, Mr. McDevitt will resign as a Director of the Company effective February 8, 2012.

 

A copy of the press release dated February 2, 2012 announcing this transition is furnished herewith as Exhibit 99.1.

 

 

Item 9.01 Financial Statements and Exhibits
   
(d) Exhibits  
   
Exhibit No. Description
99.1 Press Release of Medifast, Inc., dated February 2, 2012.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MEDIFAST, INC.  
Dated: February 2, 2012    
     
  /s/ Brendan N. Connors  
  Brendan N. Connors  
  Chief Financial Officer